CD274 and hepatocellular carcinoma: Despite currently great advancements in both diagnosis and treatment of HCC [2–5], such as therapeutic procedures, new targeted drugs and PD-1/PD-L1 inhibitors, the therapeutic efficacy of HCC is not satisfied due to poor understanding of the molecular pathogenesis of HCC and the lack of valuable biomarkers for prognosis of HCC [6].